Close

News

SkyCell assigned a critical supplier by EU Commission & Swiss Government

Vaccine supply chains must remain water-tight amid the oncoming sea of demand. With the flu season upon us and over 12.3 million confirmed cases of coronavirus, data solutions answer concerns around how to safely prepare for what’s ahead for...

Bionova Begins Construction of New Manufacturing Center

Bionova Scientific, a biologics CDMO with deep protein production, cell line development, process development and analytical expertise, has initiated construction of its new biologics manufacturing facility. Construction will be completed in approximately 10 months, with commissioning scheduled for Q3...

Moderna’s COVID-19 Vaccine Soon to Enter Phase 3 Trials as Phase 1 Shows Positive Results

Moderna, an American biotech company announced on July 14 that its COVID-19 vaccine candidate is finally going to enter the final phase on July 27 as it has shown positive results in previous human trials. Undoubtedly, this is a...

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Roche and Blueprint Medicines Corporation announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the USA, excluding Greater China*. In the US, Genentech, a member of the Roche...

Gilead presents additional data on investigational antiviral remdesivir to treat COVID-19 at Virtual COVID-19 Conference

Gilead Sciences Inc, announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir. The data are being presented at the Virtual COVID-19 Conference as part...

Glenmark reduces price of oral antiviral FabiFlu by 27% in India

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with...

Biophore India gets DCGI nod to manufacture COVID drug Favipiravir API

Biophore India Pharmaceuticals, a Hyderabad-based firm, has received license from the Drug Controller General of India (DCGI) to manufacture Favipiravir, an active pharmaceutical ingredient (API), used in the finished formulation to treat mild to moderate COVID-19 cases. Besides DCGI’s...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read